Product Defect

Migliaccio & Rathod LLP Appointed to Help Lead Valsartan Litigation

Related image

Migliaccio & Rathod LLP File Nationwide Class Action Complaint Against Major Pharmaceutical Companies for Contaminated Valsartan Sales and Are Appointed by Court to Plaintiffs’ Steering Committee

Migliaccio & Rathod, as an appointed member of the Plaintiffs’ Steering Committee and co-lead of the Medical Monitoring group, have filed a Consolidated Amended Class Action Complaint against Teva, Major Pharmaceuticals, and Solco Healthcare. This complaint is based on reports that found large quantities of the hypertension drug Valsartan, an angiotensin II receptor blocker used to treat high blood pressure and heart failure, were contaminated with a carcinogen called NDMA, which increases one’s risk of cancer after exposure. This class action litigation seeks, among other things, compensation for the plaintiffs’ losses and injuries relating to the defendants’ negligence and failure to exercise due care in the manufacturing, testing, distribution, labeling, marketing, and sale of Valsartan throughout the United States.

Did You Take Medicines Containing Valsartan and Were You Notified of the FDA’s Recall?

If so, we would like to speak with you. Please complete the contact form on this page, send an email to info@classlawdc.com or call us at (202) 470-3520 for more information.

Committed to Holding Corporations Accountable for Defective Products

The lawyers at Migliaccio & Rathod LLP have years of experience in class action litigation against large corporations and the government, including cases involving defective products.  More information about our current cases and investigations is available on our blog.

Facebooktwitterlinkedinmail